Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer

NCT01532011 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01532011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01532011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2012
Completion date
June 30, 2016
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancers, solid tumors